Evidence map›Paper›PMID 35596156›Full record

ArticleMolecular medicine (Cambridge, Mass.)2022

Glabridin, a bioactive component of licorice, ameliorates diabetic nephropathy by regulating ferroptosis and the VEGF/Akt/ERK pathways.

Hongtao Tan, Junxian Chen, Yicong Li, Yingshan Li, Yunchang Zhong, Guangzhao Li, Lingling Liu, Yiqun Li

Open access · goldAbstract read
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed, 1 pooled it
25.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 1 synthesis or guideline pooled it, 150 citations in OpenAlex.

  1. Pooled it
  2. Ferroptosis in kidney disease.Nature reviews. Nephrology · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Effect of glabridin on sperm traits, testicular oxidative status, andVeterinary research forum : an international quarterly journal · 2026
    Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025
    Article
  17. Review
  18. Review
  19. Article
  20. Article

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Hongtao TanDepartment of Traditional Chinese Medicine, Huizhou Municipal Central Hospital, Huicheng District, No. 41 Eling North Road, Huizhou, 516000, Guangdong, China.
Junxian ChenThe First College of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
Yicong LiDepartment of Traditional Chinese Medicine, Huizhou Municipal Central Hospital, Huicheng District, No. 41 Eling North Road, Huizhou, 516000, Guangdong, China.
Yingshan LiDepartment of Traditional Chinese Medicine, Huizhou Municipal Central Hospital, Huicheng District, No. 41 Eling North Road, Huizhou, 516000, Guangdong, China.
Yunchang ZhongDepartment of Traditional Chinese Medicine, Huizhou Municipal Central Hospital, Huicheng District, No. 41 Eling North Road, Huizhou, 516000, Guangdong, China.
Guangzhao LiDepartment of Traditional Chinese Medicine, Huizhou Municipal Central Hospital, Huicheng District, No. 41 Eling North Road, Huizhou, 516000, Guangdong, China.
Lingling LiuDepartment of Traditional Chinese Medicine, Huizhou Municipal Central Hospital, Huicheng District, No. 41 Eling North Road, Huizhou, 516000, Guangdong, China. liu_ling_ling@sina.cn.ORCID 0000-0001-7672-3780
Yiqun LiDepartment of Traditional Chinese Medicine, Huizhou Municipal Central Hospital, Huicheng District, No. 41 Eling North Road, Huizhou, 516000, Guangdong, China. li_yi_qun@sina.cn.
Huizhou Central People's Hospital · CNGuangzhou University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlabridin (Glab) is a bioactive component of licorice that can ameliorate diabetes, but its role in diabetic nephropathy (DN) has seldom been reported. Herein, we explored the effect and underlying mechanism of Glab on DN.

methodsThe bioactive component-target network of licorice against DN was by a network pharmacology approach. The protective effect of Glab on the kidney was investigated by a high-fat diet with streptozotocin induced-diabetic rat model. High glucose-induced NRK-52E cells were used for in vitro studies. The effects of Glab on ferroptosis and VEGF/Akt/ERK pathways in DN were investigated in vivo and in vitro using qRT-PCR, WB, and IHC experiments.

resultsBioinformatics analysis constructed a network comprising of 10 bioactive components of licorice and 40 targets for DN. 13 matching targets of Glab were mainly involved in the VEGF signaling pathway. Glab treatment ameliorated general states and reduced FBG, HOMA-β, and HOMA-insulin index of diabetic rats. The renal pathological changes and the impaired renal function (the increased levels of Scr, BUN, UREA, KIM-1, NGAL, and TIMP-1) were also improved by Glab. Moreover, Glab repressed ferroptosis by increasing SOD and GSH activity, and GPX4, SLC7A11, and SLC3A2 expression, and decreasing MDA and iron concentrations, and TFR1 expression, in vivo and in vitro. Mechanically, Glab significantly suppressed VEGF, p-AKT, p-ERK1/2 expression in both diabetic rats and HG-induced NRK-52E cells.

conclusionsThis study revealed protective effects of Glab on the kidney of diabetic rats, which might exert by suppressing ferroptosis and the VEGF/Akt/ERK pathway.

Indexed as

Diabetes Mellitus, ExperimentalDiabetic NephropathiesFerroptosisGlycyrrhizaIsoflavonesPhenolsAnimalsKidneyMAP Kinase Signaling SystemPlant ExtractsProto-Oncogene Proteins c-aktRatsVascular Endothelial Growth Factor AglabridinIsoflavonesPhenolsPlant ExtractsProto-Oncogene Proteins c-aktVascular Endothelial Growth Factor ABioinformaticsDiabetic nephropathyFerroptosisGlabridinVEGF signaling pathway

Identifiers

PMID35596156
PMCPMC9123664
OpenAlexW4280632277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.